Bulevirtide for Chronic Hepatitis D

被引：0
|
作者：
Fu, Hua [1 ]
Liu, Yang [1 ]
Liu, Qi [1 ]
机构：
[1] Guizhou Med Univ, Affiliated Hosp, Guiyang, Peoples R China
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2023年 / 389卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1247 / 1248
页数：2
相关论文
共 50 条
  • [21] Bulevirtide for patients with compensated chronic hepatitis delta: A review
    Degasperi, Elisabetta
    Anolli, Maria P.
    Lampertico, Pietro
    LIVER INTERNATIONAL, 2023, 43 : 80 - 86
  • [22] Treatment of Chronic Hepatitis D with Bulevirtide-A Fight against Two Foes-An Update
    Ferenci, Peter
    Reiberger, Thomas
    Jachs, Mathias
    CELLS, 2022, 11 (22)
  • [23] Real-world data on treatment with bulevirtide in patients with chronic hepatitis B and D coinfection
    Herta, Toni
    Hahn, Magdalena
    Maier, Melanie
    Niemeyer, Johannes
    Gerhardt, Florian
    Schumacher, Jonas
    Fischer, Janett
    Wiegand, Johannes
    Berg, Thomas
    van Boemmel, Florian
    JOURNAL OF HEPATOLOGY, 2022, 77 : S860 - S860
  • [24] No detectable resistance to bulevirtide in participants with chronic hepatitis D (CHD) through 24 weeks of treatment
    Hollnberger, Julius
    Liu, Yang
    Martin, Ross
    Manhas, Savrina
    Aeschbacher, Thomas
    Chang, Silvia
    Xu, Simin
    Han, Bin
    Yazdi, Tahmineh
    May, Lindsey
    Han, Dong
    Schoeneweis, Katrin
    Flaherty, John F.
    Suri, Vithika
    Manuilov, Dmitry
    Mateo, Roberto
    Svarovskaia, Evguenia S.
    Mo, Hongmei
    Urban, Stephan
    JOURNAL OF HEPATOLOGY, 2022, 77 : S845 - S845
  • [25] NO DETECTABLE RESISTANCE TO BULEVIRTIDE MONOTHERAPY THROUGH 96 WEEKS TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS D
    Aleman, Soo
    Liu, Yang
    Xu, Simin
    Chang, Silvia
    Martin, Ross
    Aeschbacher, Thomas
    May, Lindsey
    Manhas, Savrina
    Han, Dong
    Yazdi, Tahmineh
    Martinez, Clarissa
    Ho, Pui Yan
    Richards, Christopher
    Marceau, Caleb
    Manuilov, Dmitry
    Flaherty, John F.
    Maiorova, Evguenia
    Mo, Hongmei
    Wedemeyer, Heiner
    Lampertico, Pietro
    HEPATOLOGY, 2023, 78 : S398 - S399
  • [26] Real life kinetics of new HBV markers during treatment of chronic hepatitis D with bulevirtide
    Pronier, Charlotte
    Bomo, Jeremy
    Besombes, Juliette
    Levacher, Anita
    Brichler, Segolene
    Gripon, Philippe
    Jezequel, Caroline
    Guyader, Dominique
    Thibault, Vincent
    JOURNAL OF HEPATOLOGY, 2021, 75 : S696 - S697
  • [27] Reassessing the Safety of Bulevirtide in Chronic Hepatitis Delta: A Critical Perspective
    Asselah, Tarik
    Mercier, Renee-Claude
    Manuilov, Dmitry
    Wedemeyer, Heiner
    LIVER INTERNATIONAL, 2025, 45 (05)
  • [28] Refining the Safety Perspective of Bulevirtide in Chronic Hepatitis Delta Management
    Zhou, Ying
    Pan, Qi
    LIVER INTERNATIONAL, 2025, 45 (03)
  • [29] Antiviral therapy for chronic hepatitis D. European Commission grants full approval for bulevirtide (Hepcludex®)
    不详
    VISCERAL MEDICINE, 2023, 39 (05) : 152 - 152
  • [30] Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis
    Lampertico, P.
    Aleman, S.
    Blank, A.
    Bogomolov, P.
    Chulanov, V.
    Mamonova, N.
    Morozov, V.
    Sagalova, O.
    Stepanova, T.
    Suri, V.
    Manuilov, D.
    Ye, L.
    Flaherty, J. F.
    Osinusi, A.
    Cornberg, M.
    Brunetto, M.
    Wedemeyer, H.
    DIGESTIVE AND LIVER DISEASE, 2023, 55 : S73 - S73
12345